tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Closing Bell Movers: CSX gains over 2% on earnings beat; OZK slips on miss
PremiumThe FlyClosing Bell Movers: CSX gains over 2% on earnings beat; OZK slips on miss
17d ago
Kezar Life Sciences Faces FDA Challenges in Drug Program
Premium
Company Announcements
Kezar Life Sciences Faces FDA Challenges in Drug Program
17d ago
Kezar Life Sciences trading resumes
Premium
The Fly
Kezar Life Sciences trading resumes
17d ago
Kezar Life Sciences Advances in Autoimmune Hepatitis Trials
PremiumCompany AnnouncementsKezar Life Sciences Advances in Autoimmune Hepatitis Trials
3M ago
Kezar Life Sciences reports Q2 EPS ($1.87), consensus ($2.32)
Premium
The Fly
Kezar Life Sciences reports Q2 EPS ($1.87), consensus ($2.32)
3M ago
Cautious Hold on Kezar Life Sciences Amid Zetomipzomib Developments and Market Uncertainties
Premium
Ratings
Cautious Hold on Kezar Life Sciences Amid Zetomipzomib Developments and Market Uncertainties
4M ago
Kezar Life Sciences reports Q1 EPS ($2.27), consensus ($2.65)
PremiumThe FlyKezar Life Sciences reports Q1 EPS ($2.27), consensus ($2.65)
6M ago
Kezar Life Sciences Appoints New Principal Accounting Officer
Premium
Company Announcements
Kezar Life Sciences Appoints New Principal Accounting Officer
7M ago
Kezar Life Sciences: Promising AIH Phase II Results and Strategic FDA Engagement Justify Buy Rating
Premium
Ratings
Kezar Life Sciences: Promising AIH Phase II Results and Strategic FDA Engagement Justify Buy Rating
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100